

### Priority Partners Medical Benefit Drug Prior Authorization List

\*These prior authorization requirements impact all Priority Partners members.\*

\*\*All the drug codes listed below are subject to medical necessity prior authorization review.

\*\*\*Some drugs are subject to site-of-service (site-of-care) prior authorization in addition to medical necessity.

\*\*\*\*For certain drug classes, Priority Partners has preferred drugs. Please see this additional listing towards the bottom of this document.

HCPCS	HCPCS Description	Drug Name <i>Please note: Name examples are included for reference only. This is not an all-inclusive list.</i>	Subject to Site-of-Service prior authorization? YES (Y) or NO (N)	Effective Date
90378	Respiratory syncytial virus immune globulin (RSV-IgIM), for intramuscular use, 50 mg, each	Synagis	Y	1/1/2019
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	Orencia intravenous	Y	1/1/2019
J0178	Injection, aflibercept, 1 mg	Eylea	N	1/1/2019
J0202	Injection, alemtuzumab, 1 mg	Lemtrada	Y	1/1/2019
J0490	Injection, belimumab, 10 mg	Benlysta intravenous	Y	1/1/2019
J0585	Injection, onabotulinumtoxin a, 1 unit	Botox	Y	1/1/2019
J0586	Injection, abobotulinumtoxin a, 5 units	Dysport	Y	1/1/2019
J0587	Injection, rimabotulinumtoxin b, 100 units	Myobloc	Y	1/1/2019
J0588	Injection, incobotulinumtoxin a, 1 unit	Xeomin	Y	1/1/2019
J0717	Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	Cimzia lyophilized powder vial	Y	1/1/2019
J0897	Injection, denosumab, 1 mg	Prolia, Xgeva	Y	1/1/2019
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	Privigen	Y	1/1/2019
J1556	Injection, immune globulin (bivigam), 500 mg	Bivigam	Y	1/1/2019
J1557	Injection, immune globulin (gammalex), intravenous, non-lyophilized (e.g., liquid), 500 mg	Gammalex	Y	1/1/2019
J1559	Injection, immune globulin (hizentra), 100 mg	Hizentra	Y	1/1/2019
J1561	Injection, immune globulin (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	Gammunex-c, Gammaked	Y	1/1/2019
J1566	Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg	Gammagard S/D Less IgA	Y	1/1/2019
J1568	Injection, immune globulin (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	Octagam	Y	1/1/2019
J1569	Injection, immune globulin (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	Gammagard	Y	1/1/2019
J1572	Injection, immune globulin (flebogamma/flebogamma dif), intravenous, non-lyophilized (e.g., liquid), 500 mg	Flebogamma DIF	Y	1/1/2019
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immunoglobulin	Hyqvia	Y	1/1/2019
J1602	Injection, golimumab, 1 mg, for intravenous use	Simponi Aria	Y	1/1/2019
J1745	Injection, infliximab, excludes biosimilar, 10 mg	Remicade, Infliximab	Y	1/1/2019
J2182	Injection, mepolizumab, 1 mg	Nucala	N	1/1/2019
J2323	Injection, natalizumab, 1 mg	Tysabri	Y	1/1/2019
J2350	Injection, ocrelizumab, 1 mg	Ocrevus	Y	1/1/2019
J2357	Injection, omalizumab, 5 mg	Xolair lyophilized powder vial, prefilled syringe, auto-injector	N	1/1/2019
J2778	Injection, ranibizumab, 0.1 mg	Lucentis	N	1/1/2019
J3262	Injection, tocilizumab, 1 mg	Actemra intravenous	Y	1/1/2019
J3380	Injection, vedolizumab, intravenous, 1 mg	Entyvio	Y	1/1/2019
J7320	Hyaluronan or derivative, genvisc 850, for intra-articular injection, 1 mg	GenVisc 850	Y	1/1/2019
J7321	Hyaluronan or derivative, hyalgan or supartz or visco-3, for intra-articular injection, per dose	Hyalgan, Supartz FX, Visco-3	Y	1/1/2019
J7322	Hyaluronan or derivative, hymovis, for intra-articular injection, 1 mg	Hymovis	Y	1/1/2019
J7323	Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose	Euflexxa	Y	1/1/2019
J7324	Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose	Orthovisc	Y	1/1/2019
J7325	Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg	Synvisc, Synvisc One	Y	1/1/2019
J7326	Hyaluronan or derivative, gel-one, for intra-articular injection, per dose	Gel-one	Y	1/1/2019
J7327	Hyaluronan or derivative, monovisc, for intra-articular injection, per dose	Monovisc	Y	1/1/2019
J7328	Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg	Gelsyn 3	Y	1/1/2019
J9035	Injection, bevacizumab, 10 mg	Avastin	N	1/1/2019
J9299	Injection, nivolumab, 1 mg	Opdivo	N	1/1/2019
J9312	Injection, rituximab, 10 mg	Rituxan	Y	1/1/2019
J9355	Injection, trastuzumab, excludes biosimilar, 10 mg	Herceptin	N	1/1/2019
Q2041	Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Yescarta	N	1/1/2019
Q2042	Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Kymriah	N	1/1/2019
Q5103	Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg	Inflectra	Y	1/1/2019
Q5104	Injection, infliximab-abda, biosimilar, (renflexis), 10 mg	Renflexis	Y	1/1/2019
Q5108	Injection, pegfilgrastim-jmdb, biosimilar, (fulphila), 0.5 mg	Fulphila	N	1/1/2019
J0517	Injection, benralizumab, 1 mg	Fasenra syringe	N	4/1/2019
J1628	Injection, guselkumab, 1 mg	Tremfya	Y	4/1/2019
J3245	Injection, tildrakizumab, 1 mg	Ilumya	Y	4/1/2019
J3398	Injection, voretigene neparvovec-rzyl, 1 billion vector genomes	Luxturna	N	4/1/2019
J7318	Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg	Durolane	Y	4/1/2019
J7329	Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg	TriVisc	Y	4/1/2019
J9305	Injection, pemetrexed, 10 mg	Alimta, Pemetrexed Disodium	N	4/1/2019
J9311	Injection, rituximab 10 mg and hyaluronidase	Rituxan Hycela	Y	4/1/2019
Q5111	Injection, pegfilgrastim-cbqv, biosimilar, (udenycya), 0.5 mg	Udenycya	N	4/1/2019
J1555	Injection, immune globulin (cuvitru), 100 mg	Cuvitru	Y	7/1/2019
J1599	Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg	Panzysga	Y	7/1/2019
J3358	Ustekinumab, for intravenous injection, 1 mg	Stelara intravenous	Y	7/1/2019
Q5107	Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg	Mvasi	N	7/1/2019
J1950	Injection, leuprolide acetate (for depot suspension), per 3.75 mg	Lupron Depot (1-Month, 3-Month), Lupron Depot-Ped (1-Month, 3-Month)	N	10/1/2019
J2796	Injection, romiplostim, 10 micrograms	Nplate	N	10/1/2019
J3316	Injection, triptorelin, extended-release, 3.75 mg	Triptodur	N	10/1/2019
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	Eligard, Lupron Depot (1-Month, 3-Month, 4-Month, 6-Month)	N	10/1/2019
J9218	Leuprolide acetate, per 1 mg	Leuprolide Acetate	N	10/1/2019
J9226	Histrelin implant (supprelin la), 50 mg	Supprelin LA	N	10/1/2019

J9356	Injection, trastuzumab, 10 mg and hyaluronidase-oysk	Herceptin Hylecta	N	10/1/2019
J3111	Injection, romosozumab-aqqg, 1 mg	Evenity	Y	1/1/2020
J7331	Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg	Synojoynt	Y	1/1/2020
J7332	Hyaluronan or derivative, triluron, for intra-articular injection, 1 mg	Triluron	Y	1/1/2020
Q5112	Injection, trastuzumab-dttb, biosimilar, (ontruzant), 10 mg	Ontruzant	N	1/1/2020
Q5113	Injection, trastuzumab-pkrb, biosimilar, (herzuma), 10 mg	Herzuma	N	1/1/2020
Q5114	Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg	Ogivri	N	1/1/2020
Q5115	Injection, rituximab-abbs, biosimilar, (truxima), 10 mg	Truxima	Y	1/1/2020
Q5116	Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg	Trazimera	N	1/1/2020
Q5117	Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg	Kanjinti	N	1/1/2020
Q5118	Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg	Zirabev	N	1/1/2020
J0179	Injection, brolocizumab-dbl1, 1 mg	Beovu	N	4/1/2020
J9309	Injection, polatuzumab vedotin-piiq, 1 mg	Polivy	N	4/1/2020
J0791	Injection, crizanlizumab-tmca, 5 mg	Adakveo	N	8/1/2020
J1429	Injection, golodirsen, 10 mg	Vyondys 53	N	8/1/2020
J0598	Injection, c-1 esterase inhibitor (human), cinryze, 10 units	Cinryze	N	1/1/2021
J2326	Injection, nusinersen, 0.1 mg	Spinraza	N	1/1/2021
J3399	Injection, onasemnogene abeparvovec-xioi, per treatment, up to 5x10 <sup>15</sup> vector genomes	Zolgensma	N	1/1/2021
J1300	Injection, eculizumab, 10 mg	Soliris	Y	3/1/2021
J1303	Injection, ravulizumab-cwvz, 10 mg	Ultomiris	Y	3/1/2021
J1322	Injection, elosulfase alfa, 1 mg	Vimizim	N	3/1/2021
J7189	Factor viia (antihemophilic factor, recombinant), per 1 microgram	NovoSeven RT	N	3/1/2021
J9216	Injection, interferon, gamma 1-b, 3 million units	Actimmune	N	3/1/2021
Q5122	Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg	Nyvepria	N	3/1/2021
J0223	Injection, givosiran, 0.5 mg	Givlaari	Y	4/1/2021
J1554	Injection, immune globulin (asceniv), 500 mg	Asceniv	Y	4/1/2021
J1558	Injection, immune globulin (xembify), 100 mg	Xembify	Y	4/1/2021
J3032	Injection, eptinezumab-jjmr, 1 mg	Vyepti	Y	4/1/2021
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	Ruxience	Y	4/1/2021
Q5120	Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg	Ziextenzo	N	4/1/2021
Q5121	Injection, infliximab-axxq, biosimilar, (avsola), 10 mg	Avsola	Y	4/1/2021
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (*product previously required PA under J2505 effective 1/1/2019)	Neulasta, Neulasta Onpro	N	1/1/2022
J0172	Injection, aducanumab-avwa, 2 mg	Aduhelm	N	8/1/2022
J0180	Injection, agalsidase beta, 1 mg	Fabrazyme	N	8/1/2022
J0221	Injection, alglucosidase alfa, (lumizyme), 10 mg	Lumizyme	Y	8/1/2022
J0222	Injection, patisiran, 0.1 mg	Onpattro	Y	8/1/2022
J0224	Injection, lumasiran, 0.5 mg	Oxlumo	N	8/1/2022
J0256	Injection, alpha 1 proteinase inhibitor (human), not otherwise specified, 10 mg	Aralast NP, Prolastin-C, Zemaira	Y	8/1/2022
J0257	Injection, alpha 1 proteinase inhibitor (human), (glassia), 10 mg	Glassia	Y	8/1/2022
J0364	Injection, apomorphine hydrochloride, 1 mg	Apokyn, Apomorphine	N	8/1/2022
J0567	Injection, cerliponase alfa, 1 mg	Brineura	N	8/1/2022
J0584	Injection, burosumab-twza 1 mg	Crysvita	Y	8/1/2022
J0593	Injection, lanadelumab-flyo, 1 mg (code may be used for medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)	Takhzyro	N	8/1/2022
J0596	Injection, c1 esterase inhibitor (recombinant), ruconest, 10 units	Ruconest	N	8/1/2022
J0597	Injection, c-1 esterase inhibitor (human), berinert, 10 units	Beriner	Y	8/1/2022
J0599	Injection, c-1 esterase inhibitor (human), (haegarda), 10 units	Haegarda	N	8/1/2022
J0606	Injection, etelcalcetide, 0.1 mg	Parsabiv	N	8/1/2022
J0638	Injection, canakinumab, 1 mg	Ilaris	N	8/1/2022
J0642	Injection, levoleucovorin (khapszory), 0.5 mg	Khapzory	N	8/1/2022
J0741	Injection, cabotegravir and rilpivirine, 2mg/3mg	Cabenuva	Y	8/1/2022
J0775	Injection, collagenase, clostridium histolyticum, 0.01 mg	Xiaflex	N	8/1/2022
J0894	Injection, decitabine, 1 mg	Decitabine	N	8/1/2022
J0895	Injection, deferoxamine mesylate, 500 mg	Desferal, Deferoxamine Mesylate	N	8/1/2022
J1290	Injection, ecallantide, 1 mg	Kalbitor	N	8/1/2022
J1301	Injection, edaravone, 1 mg	Radicava	Y	8/1/2022
J1305	Injection, evinacumab-dgnb, 5mg	Evkeeza	Y	8/1/2022
J1325	Injection, epoprostenol, 0.5 mg	Flolan, Veletri, Epoprostenol Sodium	N	8/1/2022
J1426	Injection, casimersen, 10 mg	Amondys 45	N	8/1/2022
J1427	Injection, viltolarsen, 10 mg	Viltepso	N	8/1/2022
J1428	Injection, eteplirsen, 10 mg	Exondys 51	N	8/1/2022
J1442	Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram	Neupogen	N	8/1/2022
J1447	Injection, tbo-filgrastim, 1 microgram	Granix	N	8/1/2022
J1448	Injection, trilaciclib, 1 mg	Cosela	N	8/1/2022
J1458	Injection, galsulfase, 1 mg	Naglazyme	N	8/1/2022
J1460	Injection, gamma globulin, intramuscular, 1 cc	GamaSTAN	N	8/1/2022
J1743	Injection, idursulfase, 1 mg	Elaprase	N	8/1/2022
J1744	Injection, icatibant, 1 mg	Firazyr, Sajazir, Icatibant Acetate	N	8/1/2022
J1786	Injection, imiglucerase, 10 units	Cerezyme	Y	8/1/2022
J1823	Injection, inebilizumab-cdon, 1 mg	Uplizna	N	8/1/2022
J1930	Injection, lanreotide, 1 mg	Somatuline Depot, Lanreotide Acetate	Y	8/1/2022
J1931	Injection, laronidase, 0.1 mg	Aldurazyme	N	8/1/2022
J1951	Injection, leuprolide acetate for depot suspension (fensolvi), 0.25 mg	Fensolvi (6 Month)	N	8/1/2022
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg	Sandostatin LAR Depot	Y	8/1/2022
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg	Sandostatin, Octreotide Acetate	N	8/1/2022
J2502	Injection, pasireotide long acting, 1 mg	Signifor LAR	N	8/1/2022
J2507	Injection, pegloticase, 1 mg	Krystexxa	N	8/1/2022
J2786	Injection, reslizumab, 1 mg	Cinqair	N	8/1/2022
J2793	Injection, riloncept, 1 mg	Arcalyst	N	8/1/2022
J2820	Injection, sargramostim (gm-csf), 50 mcg	Leukine	N	8/1/2022
J2840	Injection, sebelipase alfa, 1 mg	Kanuma	N	8/1/2022
J2860	Injection, siltuximab, 10 mg	Sylvant	N	8/1/2022
J3060	Injection, taliglucerase alfa, 10 units	Elelyso	N	8/1/2022
J3145	Injection, testosterone undecanoate, 1 mg	Aveed	N	8/1/2022
J3241	Injection, teprotumumab-trbw, 10 mg	Tepezza	N	8/1/2022
J3285	Injection, treprostinil, 1 mg	Remodulin, Treprostinil	N	8/1/2022
J3315	Injection, triptorelin pamoate, 3.75 mg	Trelstar Mixject	N	8/1/2022
J3385	Injection, velaglucerase alfa, 100 units	Vpriv	N	8/1/2022
J3396	Injection, verteporfin, 0.1 mg	Visudyne	N	8/1/2022
J3397	Injection, vestronidase alfa-vjkb, 1 mg	Mepsevii	N	8/1/2022

J3489	Injection, zoledronic acid, 1 mg	Reclast, Zoledronic Acid	N	8/1/2022
J7170	Injection, emicizumab-kxwh, 0.5 mg	Hemlibra	N	8/1/2022
J7175	Injection, factor x, (human), 1 i.u.	Coagadex	N	8/1/2022
J7177	Injection, human fibrinogen concentrate (fibryga), 1 mg	Fibryga	N	8/1/2022
J7178	Injection, human fibrinogen concentrate, not otherwise specified, 1 mg	RiaSTAP	N	8/1/2022
J7179	Injection, von willebrand factor (recombinant), (vonvendi), 1 i.u. vwf:rho	Vonvendi	N	8/1/2022
J7181	Injection, factor xiii a-subunit, (recombinant), per iu	Tretten	N	8/1/2022
J7182	Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu	Novoeight	N	8/1/2022
J7183	Injection, von willebrand factor complex (human), wilate, 1 i.u. vwf:rho	Wilate	N	8/1/2022
J7185	Injection, factor viii (antihemophilic factor, recombinant) (xyntha), per i.u.	Xyntha, Xyntha Solofuse	N	8/1/2022
J7186	Injection, antihemophilic factor viii/von willebrand factor complex (human), per factor viii i.u.	Alphanate	N	8/1/2022
J7187	Injection, von willebrand factor complex (humate-p), per iu vwf:rho	Humate-P	N	8/1/2022
J7188	Injection, factor viii (antihemophilic factor, recombinant), (obizur), per i.u.	Obizur	N	8/1/2022
J7190	Factor viii (antihemophilic factor, human) per i.u.	Hemofil M, Koate, Koate-DVI	N	8/1/2022
J7192	Factor viii (antihemophilic factor, recombinant) per i.u., not otherwise specified	Advate, Kogenate FS, Recombinate	N	8/1/2022
J7193	Factor ix (antihemophilic factor, purified, non-recombinant) per i.u.	AlphaNine SD	N	8/1/2022
J7194	Factor ix, complex, per i.u.	Profilnine	N	8/1/2022
J7195	Injection, factor ix (antihemophilic factor, recombinant) per iu, not otherwise specified	BeneFIX	N	8/1/2022
J7198	Anti-inhibitor, per i.u.	Feiba	N	8/1/2022
J7200	Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu	Rixubis	N	8/1/2022
J7201	Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u.	Alprolix	N	8/1/2022
J7202	Injection, factor ix, albumin fusion protein, (recombinant), idelvion, 1 i.u.	Idelvion	N	8/1/2022
J7203	Injection factor ix, (antihemophilic factor, recombinant), glycopegylated, (rebinyn), 1 iu	Rebinyn	N	8/1/2022
J7204	Injection, factor viii, antihemophilic factor (recombinant), (esperoct), glycopegylated-exei, per iu	Esperoct	N	8/1/2022
J7205	Injection, factor viii fc fusion protein (recombinant), per iu	Eloctate	N	8/1/2022
J7207	Injection, factor viii, (antihemophilic factor, recombinant), pegylated, 1 i.u.	Adynovate	N	8/1/2022
J7208	Injection, factor viii, (antihemophilic factor, recombinant), pegylated-aucl, (jivi), 1 i.u.	Jivi	N	8/1/2022
J7209	Injection, factor viii, (antihemophilic factor, recombinant), (nuwiq), 1 i.u.	Nuwiq	N	8/1/2022
J7210	Injection, factor viii, (antihemophilic factor, recombinant), (afstyla), 1 i.u.	Afstyla	N	8/1/2022
J7211	Injection, factor viii, (antihemophilic factor, recombinant), (kovaltry), 1 i.u.	Kovaltry	N	8/1/2022
J7212	Factor viia (antihemophilic factor, recombinant)-jncw (sevenfact), 1 microgram	Sevenfact	N	8/1/2022
J7340	Carbidopa 5 mg/levodopa 20 mg enteral suspension, 100 ml	Duopa	N	8/1/2022
J7352	Afamelanotide implant, 1 mg	Scenesse	N	8/1/2022
J9015	Injection, aldesleukin, per single use vial	Proleukin	N	8/1/2022
J9022	Injection, atezolizumab, 10 mg	Tecentriq	N	8/1/2022
J9023	Injection, avelumab, 10 mg	Bavencio	N	8/1/2022
J9025	Injection, azacitidine, 1 mg	Vidaza, Azacitidine	N	8/1/2022
J9033	Injection, bendamustine hcl (treanda), 1 mg	Treanda	N	8/1/2022
J9034	Injection, bendamustine hcl (bendeka), 1 mg	Bendeka	N	8/1/2022
J9036	Injection, bendamustine hydrochloride, (belrapzo/bendamustine), 1 mg	Belrapzo	N	8/1/2022
J9037	Injection, belantamab mafodotin-blmf, 0.5 mg	Blenrep	N	8/1/2022
J9039	Injection, blinatumomab, 1 microgram	Blinicyto	N	8/1/2022
J9041	Injection, bortezomib (velcade), 0.1 mg	Velcade, Bortezomib	N	8/1/2022
J9042	Injection, brentuximab vedotin, 1 mg	Adcetris	N	8/1/2022
J9043	Injection, cabazitaxel, 1 mg	Jevtana	N	8/1/2022
J9047	Injection, carfilzomib, 1 mg	Kyprolis	N	8/1/2022
J9055	Injection, cetuximab, 10 mg	Erbix	N	8/1/2022
J9057	Injection, copanlisib, 1 mg	Aliqopa	N	8/1/2022
J9119	Injection, cemiplimab-rwlc, 1 mg	Libtayo	N	8/1/2022
J9144	Injection, daratumumab, 10 mg and hyaluronidase-fihj	Darzalex Faspro	N	8/1/2022
J9145	Injection, daratumumab, 10 mg	Darzalex	N	8/1/2022
J9155	Injection, degarelix, 1 mg	Firmagon, Firmagon (240 MG Dose)	N	8/1/2022
J9171	Injection, docetaxel, 1 mg	Docetaxel	N	8/1/2022
J9173	Injection, durvalumab, 10 mg	Imfinzi	N	8/1/2022
J9176	Injection, elotuzumab, 1 mg	Empliciti	N	8/1/2022
J9177	Injection, enfortumab vedotin-ejfv, 0.25 mg	Padcev	N	8/1/2022
J9179	Injection, eribulin mesylate, 0.1 mg	Halaven	N	8/1/2022
J9201	Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg	Gemcitabine	N	8/1/2022
J9202	Goserelin acetate implant, per 3.6 mg	Zoladex	N	8/1/2022
J9204	Injection, mogamulizumab-kpkc, 1 mg	Poteligeo	N	8/1/2022
J9207	Injection, ixabepilone, 1 mg	Ixempra Kit	N	8/1/2022
J9210	Injection, emapalumab-lzsg, 1 mg	Gamifant	N	8/1/2022
J9223	Injection, lurbinectedin, 0.1 mg	Zepzelca	N	8/1/2022
J9227	Injection, isatuximab-irfc, 10 mg	Sarclisa	N	8/1/2022
J9228	Injection, ipilimumab, 1 mg	Yervoy	N	8/1/2022
J9229	Injection, inotuzumab ozogamicin, 0.1 mg	Besponsa	N	8/1/2022
J9262	Injection, omacetaxine mepesuccinate, 0.01 mg	Synribo	N	8/1/2022
J9263	Injection, oxaliplatin, 0.5 mg	Oxaliplatin	N	8/1/2022
J9264	Injection, paclitaxel protein-bound particles, 1 mg	Abraxane, Paclitaxel Protein-Bound Particles	N	8/1/2022
J9266	Injection, pegaspargase, per single dose vial	Oncaspar	N	8/1/2022
J9269	Injection, tagraxofusp-erzs, 10 micrograms	Elzonris	N	8/1/2022
J9271	Injection, pembrolizumab, 1 mg	Keytruda	N	8/1/2022
J9301	Injection, obinutuzumab, 10 mg	Gazyva	N	8/1/2022
J9302	Injection, ofatumumab, 10 mg	Arzerra	N	8/1/2022
J9303	Injection, panitumumab, 10 mg	Vectibix	N	8/1/2022
J9306	Injection, pertuzumab, 1 mg	Perjeta	N	8/1/2022
J9307	Injection, pralatrexate, 1 mg	Folotyn, Pralatrexate	N	8/1/2022
J9308	Injection, ramucirumab, 5 mg	Cyramza	N	8/1/2022
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg	Lumoxiti	N	8/1/2022
J9315	Injection, romidepsin, 1 mg	Istodax	N	8/1/2022
J9317	Injection, sacituzumab govitecan-hziy, 2.5 mg	Trodelyv	N	8/1/2022
J9318	Injection, romidepsin, non-lyophilized, 0.1 mg	Romidepsin	N	8/1/2022
J9319	Injection, romidepsin, lyophilized, 0.1 mg	Romidepsin	N	8/1/2022
J9325	Injection, talimogene laherparepvec, per 1 million plaque forming units	Imlygic	N	8/1/2022
J9330	Injection, temsirolimus, 1 mg	Torisel, Temsirolimus	N	8/1/2022
J9349	Injection, tafasitamab-cxix, 2 mg	Monjuvi	N	8/1/2022
J9354	Injection, ado-trastuzumab emtansine, 1 mg	Kadcyla	N	8/1/2022
J9358	Injection, fam-trastuzumab deruxtecan-nxki, 1 mg	Enhertu	N	8/1/2022
J9395	Injection, fulvestrant, 25 mg	Faslodex, Fulvestrant	N	8/1/2022
J9400	Injection, ziv-aflibercept, 1 mg	Zaltrap	N	8/1/2022



Q2053	Brexucabtagene autoleucl, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Tecartus	N	8/1/2022
Q2054	Lisocabtagene maraleucl, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Breyanzi	N	8/1/2022
Q4074	Iloprost, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 20 micrograms	Ventavis	N	8/1/2022
Q5101	Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram	Zarxio	N	8/1/2022
Q5110	Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram	Nivestym	N	8/1/2022
Q5123	Injection, rituximab-arrx, biosimilar, (riabni), 10 mg	Riabni	N	8/1/2022
Q2055	Idecabtagene vicleucl, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose	Abecma	N	3/1/2023
C9047	Injection, caplacizumab-yhdp, 1 mg	Cablivi	N	3/1/2023
Q2056	Ciltacabtagene autoleucl, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose (Code Price is for drug only)	Carvykti	N	3/1/2023
J9331	Injection, sirolimus protein-bound particles, 1 mg	Fyarro	N	3/1/2023
J9274	Injection, tebentafusp-tebn, 1 microgram	Kimtrak	N	3/1/2023
J0219	Injection, avalglucosidase alfa-ngpt, 4 mg	Nexvazyme	N	3/1/2023
J2998	Injection, plasminogen, human-tvmh, 1 mg	Ryplazim	N	3/1/2023
J2327	Injection, risankizumab-rzaa, intravenous, 1 mg	Skyrizi intravenous	N	3/1/2023
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	Byooviz	N	5/1/2023
Q5125	Injection, filgrastim-ayow, biosimilar, (releuko), 1 mcg	Releuko	N	5/1/2023
Q5126	Injection, bevacizumab-maly, biosimilar, (alymSYS), 10 mg	Alymsys	N	5/1/2023
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	Stimufend	N	5/1/2023
Q5128	Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg	Cimerli	N	5/1/2023
Q5129	Injection, bevacizumab-adcd (vegzelma), biosimilar, 10 mg	Vegzelma	N	5/1/2023
Q5130	Injection, pegfilgrastim-pbbk (flyneta), biosimilar, 0.5 mg	Flyneta	N	5/1/2023
J9196	Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to J9201, 200 mg	Gemcitabine	N	7/1/2023
J9294	Injection, pemetrexed (hospira) not therapeutically equivalent to j9305, 10 mg	Pemetrexed Disodium	N	7/1/2023
J9296	Injection, pemetrexed (accord) not therapeutically equivalent to j9305, 10 mg	Pemetrexed Disodium	N	7/1/2023
J9297	Injection, pemetrexed (sandoz), not therapeutically equivalent to j9305, 10 mg	Pemetrexed Disodium	N	7/1/2023
J0893	Injection, decitabine (sun pharma) not therapeutically equivalent to j0894, 1 mg	Decitabine	N	7/1/2023
J9046	Injection, bortezomib, (dr. reddy's), not therapeutically equivalent to j9041, 0.1 mg	Bortezomib	N	7/1/2023
J9048	Injection, bortezomib (fresenius kabi), not therapeutically equivalent to j9041, 0.1 mg	Bortezomib	N	7/1/2023
J9049	Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg	Bortezomib	N	7/1/2023
J1411	Injection, etranacogene dezaparovec-drlb, per therapeutic dose	Hemgenix	N	7/1/2023
J2356	Injection, tezepelumab-ekko, 1 mg	Tezspire vial and syringe	N	7/1/2023
J1952	Leuprolide injectable, (camcevi), 1 mg	Camcevi	N	7/1/2023
J1576	Injection, immune globulin (Panzysga), intravenous, non-lyophilized (e.g., liquid), 500 mg	Panzysga	Y	10/1/2023
J7213	Injection, coagulation factor IX (recombinant), Ixinity, 1 IU	Ixinity	N	10/1/2023
J9056	Injection, bendamustine HCl (Vivimusta), 1 mg	Vivimusta	N	10/1/2023
J9058	Injection, bendamustine HCl (Apotex), 1 mg	Bendamustine	N	10/1/2023
J9059	Injection, bendamustine HCl (Baxter), 1 mg	Bendamustine	N	10/1/2023
J9259	Injection, paclitaxel protein-bound particles (American Regent) not therapeutically equivalent to J9264, 1 mg	Paclitaxel Protein-Bound Particles	N	10/1/2023
J9314	Injection, pemetrexed (teva) not therapeutically equivalent to J9305, 10 mg	Pemetrexed Disodium	N	10/1/2023
J9322	Injection, pemetrexed (BluePoint) not therapeutically equivalent to J9305, 10 mg	Pemetrexed Disodium	N	10/1/2023
J0801	Injection, corticotropin (acthar gel), up to 40 units (replaces J0800)	Acthar Gel	N	10/1/2023
J0802	Injection, corticotropin (ani), up to 40 units (replaces J0800)	Cortrophin	N	10/1/2023
J7199	Hemophilia clotting factor, not otherwise classified	Altuviiio	N	11/1/2023
J7214	Injection, factor viii/von willebrand factor complex, recombinant (altuviiio), per factor viii i.u.	Altuviiio	N	11/1/2023
J0225	Injection, vutrisiran, 1 mg	Amvuttra	N	11/1/2023
J9063	Injection, mirvetuximab soravtansine-gynx, 1 mg	Elahere	N	11/1/2023
J9380	Injection, teclistamab-cqyv, 0.5 mg	Tecvayli	N	11/1/2023
J0218	Injection, olipudase alfa-rpcp, 1 mg	Xenpozyme	N	11/1/2023
J2329	Injection, ublituximab-xiiy, 1mg	Briumvi	N	4/1/2024
J2777	Injection, faricimab-svoa, 0.1 mg	Vabysmo	N	4/1/2024
J1954	Injection, leuprolide acetate for depot suspension (cipla), 7.5 mg	Leuprolide Depot (3-month)	N	4/1/2024
J9394	Injection, fulvestrant (fresenius kabi) not therapeutically equivalent to j9395, 25 mg	Fulvestrant	N	4/1/2024
J1413	Injection, delandistrogene moxeparovec-rokl, per therapeutic dose	Elevidys	N	4/1/2024
J0217	Injection, velmanase alfa-tycv, 1 mg	Lamzede	N	4/1/2024
J9348	Injection, naxitamab-gqgk, 1 mg	Danyelza	N	4/1/2024
J0177	Injection, aflibercept hd, 1 mg	Eylea HD	N	6/1/2024
J0589	Injection, daxibotulinumtoxina-lanm, 1 unit	Daxxify	N	6/1/2024
J1203	Injection, cipaglucosidase alfa-atga, 5 mg	Pombiliti	N	6/1/2024
J1202	Miglustat, oral, 65 mg	Opfolda	N	6/1/2024
J3055	Injection, talquetamab-tgvs, 0.25 mg	Talvey	N	6/1/2024
J1323	Injection, elranatamab-bcmm, 1 mg	Elfrexio	N	6/1/2024

**\*\*\*\*Preferred Medical Injectable Drug List - EFFECTIVE 4/1/2024\*\*\*\***

The following is a list of preferred drugs. Use of preferred product(s) is required prior to coverage of non-preferred product(s).  
An exception process is in place for specific circumstances that may warrant a need for a non-preferred product.

2024 Drug Class	2024 Non-Preferred Products	2024 Preferred Products
<b>Autoimmune Infused Infliximab</b>	Infliximab Remicade Renflexis	Avsola Inflectra
<b>Bevacizumab</b>	Alymsys Avastin Vegzelma Zirabev	Mvasi
<b>Botulinum Toxins</b>	Botox Myobloc Xeomin	Dysport
<b>Hematologic, Neutropenia Colony Stimulating Factors – Long Acting</b>	Flyneta Nyvepria Stimufend Udenyca Ziextenzo	Fulphila Neulasta
<b>Hereditary Angioedema</b>	Berinert	Ruconest
<b>Lysosomal Storage Disorders – Gaucher Disease</b>	Elelyso VPRIV	Cerezyme

<b>Multiple Sclerosis (Infused)</b>	Briumvi Lemtrada	Ocrevus Tysabri
<b>Osteoarthritis, Viscosupplements- Multi Injection</b>	Gelsyn-3 GenVisc Hyalgan Hymovis Orthovisc Supartz-FX TriVisc Visco-3 Synvisc	Euflexxa
<b>Osteoarthritis, Viscosupplements- Single Injection</b>	Gel-One Monovisc Synvisc-One	Durolane
<b>Retinal Disorder Agents- (ARMD) Age-Related Macular Degeneration</b>	Beovu Byooviz Cimerli Lucentis Vabysmo	Avastin Eylea ( <i>*this is a preferred medication secondary to Avastin</i> )
<b>Trastuzumab</b>	Herceptin Herceptin Hylecta Herzuma Ogivri Ontruzant Trazimera	Kanjinti

\*Non-preferred product(s) are only available if process exception criteria are met when prior authorization is required. Please check the above Prior Authorization list.

The listed HCPCS Drug Codes are subject to change in accordance with the Centers for Medicare and Medicaid (CMS) coding approval updates. Prior authorization requirements instituted for the initial HCPCS code are applicable for any replacement HCPCS Code.

Submitting medical benefit drug prior authorization:

1. An electronic prior authorization request may be submitted through NovoLogix using the Priority Partners Availity secure provider portal.
2. If Availity is not able to be accessed, providers may contact NovoLogix for assistance by calling: 844-345-2803.